Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Camp Lejeune Cases
  • Drug Injury
  • Free Case Evaluation
  • About Us

EU Calls for Strengthened and Revised Warnings for MS Drug Gilenya

December 19, 2017 By Law Offices of Thomas J. Lamb, P.A.


UPDATE: 

On December 15, 2017, the FDA released an updated drug label for Gilenya with increased warnings.

(12/27/17).


Background

After conducting a routine review of the immunosuppressive drug Gilenya (fingolimod), the Medicines and Healthcare Products Regulatory Agency (MHRA) recently suggested that the drug label for Gilenya be strengthened and revised.

Gilenya is typically used to treat multiple sclerosis (MS) patients whose disease is severe in nature, or is rapidly progressing.  It is also used when at least one disease-modifying therapy has failed to improve the patient’s condition.

 

Cardiac Risks

While Gilenya is not recommended for patients who have a known risk for adverse cardiovascular events, use of the drug has yet to be contraindicated in such patients.

In light of recent findings, however, the EU advised that these warnings be strengthened to contraindications for patients with underlying cardiac disorders.

They based their decision on the following information:

A recent routine EU review identified 44 post-marketing reports of serious ventricular tachyarrhythmia and 6 reports of sudden death worldwide in patients taking [Gilenya (fingolimod)] up to the end of February 2017.

Additionally, in early treatment, Gilenya was found to have the potential to cause cardiac problems such as:

  • Persistent bradycardia, which can increase the risk of serious cardiac arrhythmias;
  • Transient bradycardia; and,
  • Second-degree or third-degree atrioventricular (AV) block.

Risks of Cancers and Serious Infections

Gilenya has also been shown to increase the risk of lymphoma and skin cancers as well as serious opportunistic infections, due to its immunosuppressive nature.

Accordingly, the EU has also called for strengthened warnings of the following side effects:

  • Lymphoma
  • Skin cancers
    • Malignant melanoma
    • Squamous cell carcinoma
    • Kaposi sarcoma
    • Merkel cell carcinoma
  • Serious opportunistic infections
    • Fatal fungal infections
    • Cryptococcal meningitis

 

Possible Changes

Back in 2015, the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) reviewed research on Gilenya and its association with progressive multifocal leukoencephalopathy (PML), a rare brain disease that often leads to death.

In light of the information these agencies uncovered, they deemed it necessary to alter the drug label for Gilenya to include PML as a potential adverse reaction.  The most recent drug label for Gilenya includes this warning (accessed 12/18/17).

As new information concerning potential side effects of Gilenya surfaces, it will be interesting to monitor the actions of these regulatory agencies.  Perhaps a new Gilenya drug label will soon be required for this drug in the U.S.

We will continue to monitor the medical and regulatory literature concerning Gilenya, and report on any significant findings.

 

Written by: Heather Helmendach, Legal Assistant 
Law Offices of Thomas J. Lamb, P.A.

 

Drug Injury Watch: Side Effects News & Reports

Drug Injury Law: Medical & Legal Information

Filed Under: Unsafe Drugs Tagged With: cardiovascular events, drug label warnings, EMA, EU, European Medicines Agency, FDA, fingolimod, food and drug administration, Gilenya, gilenya side effects, immunosuppressive drugs, lymphoma, MHRA, MS drugs, multiple sclerosis drugs, pml, serious infections, skin cancers

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • PFAS Firefighter Gear Lawsuits
  • Camp Lejeune Cases
  • GenX Water Cancer Cases
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Philips Breathing Devices Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.